Envestnet Asset Management Inc. Sells 1,256 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Envestnet Asset Management Inc. cut its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 6.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,694 shares of the company’s stock after selling 1,256 shares during the period. Envestnet Asset Management Inc. owned 0.49% of Invesco Biotechnology & Genome ETF worth $1,310,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 30.0% in the fourth quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock worth $43,000 after acquiring an additional 150 shares during the period. Millstone Evans Group LLC bought a new position in Invesco Biotechnology & Genome ETF in the 4th quarter worth about $64,000. Jones Financial Companies Lllp grew its holdings in Invesco Biotechnology & Genome ETF by 52.9% during the 4th quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after buying an additional 801 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in Invesco Biotechnology & Genome ETF during the 4th quarter valued at about $161,000. Finally, Jane Street Group LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter valued at about $295,000.

Invesco Biotechnology & Genome ETF Trading Up 0.3 %

PBE stock opened at $61.71 on Wednesday. The firm has a 50 day moving average of $62.98 and a 200-day moving average of $66.74. The firm has a market capitalization of $222.16 million, a P/E ratio of 21.05 and a beta of 0.83. Invesco Biotechnology & Genome ETF has a 12 month low of $54.52 and a 12 month high of $72.84.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.